Patanjali Ayurved has launched a drug that they claim cures the novel coronavirus, COVID-19. ICMR & Ayush Ministry have urged Patanjali Ayurved to stop promoting Coronil and Swaswari Vati as cures, verify claims and submit results of their clinical trials before going to market with said drugs. Dr Narendra Bhatt, Ayurveda Consultant & Researcher, says that the law is clear on launching ayurvedic products in 2 categories - one is classical product and the other is proprietary medicine, earlier known as patented proprietary product. When one launches a proprietary medicine, one needs to justify the composition of the medicine based on ayurvedic rationale and logic of those ingredients and the claims made thereof. Nobody can claim a cure that hasn't been approved. Murali Neelakantan, Lawyer & Former global general counsel at Cipla and Glenmark, many years ago, the process for approving or marketing an ayurvedic drug was in divergence from allopathy. Over the last 10 years, there has been a convergence in processes - allopathic and ayurvedic drugs with new ingredient mixes now undergo the same amount of scrutiny and clinical trial results from regulators. Watch BOOM's Govind Ethiraj interview Dr Narendra Bhatt and Murali Neelakantan on how do such drugs launch, allopathic or ayurvedic, what are the due processes to be followed and how does the consumer know if safe due processes are followed or not.